The PhagoCure Platform
Designed for a one-time treatment, it enables a highly targeted genetic correction in phagocytes.
Backed by top-tier partners like the University of Zurich and the Wyss Zurich Translational Center, we’re advancing a pipeline of first- and best-in-class therapies with real potential to transform lives across immunology, neurology, and metabolic disorders.
01
Precision by Design
Our unique vector engineering starts with a deep understanding of disease biology. We’ve combined clinically validated LV-SIN backbones with myeloid-specific, silencing-resistant promoters to ensure our therapies are activated precisely where they’re needed—only in differentiated phagocytes.
02
Proven in pre-clinical Models
Traditional vectors can cause unintended gene activation in stem cells, leading to severe side effects. Our design avoids this by activating only during the natural transition of stem cells into phagocytes. This built-in safety mechanism has been validated through gold-standard preclinical testing, both in vitro and in vivo.
03
Durable, Long-acting, Efficacy
Our design resists epigenetic silencing—a key reason why many gene therapies lose effectiveness over time. In both cell-based assays and long-term animal studies, PhagoCure vectors have shown sustained gene expression, outperforming other systems and supporting the promise of a lifelong therapeutic effect.
We intent to cure
Phagocyte Disorders
A Pipeline of Breakthrough Programs
Overview
01
We’re pioneering a novel therapeutic platform designed to maximize efficacy and safety – while accelerating development timelines and minimizing capital intensity.
The Future of Genetic Medicine
We combine deep expertise in gene therapy and phagocyte biology to unlock curative potential for patients with severe, underserved diseases. Using next-generation LV-SIN vectors, we engineer a patient’s own blood stem cells to produce therapeutic proteins—offering a one-time treatment that targets the root cause of disease. Our scalable platform is built to address a wide range of phagocyte-related disorders, aiming to transform care where current options fall short.